strategies and best practices for improving outcomes in ... · hypertension of the european society...
TRANSCRIPT
Strategies and Best Practices for Improving Outcomes in Pulmonary Arterial Hypertension.
Today’s Faculty
Martha Kingman, FNP-C, DNPFamily Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, TX
Objectives
»
»
»
PAH: Definition, WHO Group
Classification, Risk Assessment,
Diagnosis, and Functional
Capacity Classification
Sandra Lombardi, RN
Clinical Care Coordinator
Pulmonary Vascular Program
University of California, San Diego
San Diego, CA
How is PAH Defined?
»
»
McLaughlin VV et al. Circulation, 2009: 119:2250-2294. Hoeper MM et al. J AM Coll Cardiol, 2013; 62 (25 Suppl):D42-D50.Simonneau G, et al. Eur Respir J. 2019;53(1):1801913.
Historic Hemodynamics Definition of PAH: ◼mPAP ≥ 25 mmHg◼PAWP ≤15 mmHg◼PVR > 3 Wood units
New Proposed Hemodynamic Definition of PAH: ◼mPAP ≥ 20 mmHg◼PAWP ≤15 mmHg◼PVR > 3 Wood units
1. Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic PAH (IPAH)
1.2 Heritable PAH1.2.1 BMPR21.2.2 Unknown
1.3 Drug and toxin induced PAH
1.4 Associated PAH1.4.1 Connective tissue disease1.4.2 HIV infection1.4.3 Portal hypertension1.4.4 Congenital heart disease1.4.5 Schistosomiasis
1.5 PAH long-term responders to calcium channel blockers
1.6 Pulmonary veno-occlusive disease (PVOD) and or pulmonary capillary haemangiomatosis (PCH)
1.7 Persistent pulmonary hypertension of the newborn (PPHN)
Clinical Classification of Pulmonary Hypertension (Nice, 2018)
•Simonneau G, et al. Eur Respir J. 2019;53(1):1801913.
2. PH due to left heart disease
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular disease
2.4 Congenital/acquired cardiovascular conditions leading to post-capillary
3. PH due to lung disease and/or hypoxia
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
4.1 Chronic thromboembolic pulmonary hypertension
4.2 Other pulmonary artery obstructions
5. PH with unclear multifactorial mechanism
5.1 Hematologic disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
5.5. Sarcoidosis
Exercise PH is not defined due to lack of evidence to make a recommendation.
PAH: pulmonary arterial hypertension; PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary hemangiomatous; LVEF: left ventricular ejection fraction.
Functional Assessment of PAH
Adapted from Rubin LJ. Chest, 2004; 126 (1 Suppl): 7S-10S.
NYHA Functional ClassificationClass I No symptoms with ordinary physical activity
Class II Symptoms with ordinary activity. Slight limitation of activity
Class III Symptoms with less than ordinary activity. Marked limitation of activity
Class IV Symptoms with any activity or even at rest
Adapted from:1. Trembath RC, Harrison R. Pediatr Res, 2003; 53:883-888. 2. Minai OA, Budev MM. Cleve Clin J Med, 2007; 74:737-747. *These observations are based on reports from in vitro, animal, and human trials. The clinical significance is unknown.
Progression of PAH*
ASYMPTOMATIC1 SYMPTOMATIC/DECOMPENSATING1
DECLINING/DECOMPENSATED2
TIMERAPPVR
PAP
CO
RIGHT HEART DYSFUNCTION RIGHT HEART FAILURE
Risk Factors for the Development of PAH
Drugs and Toxins Known to Induce PAH
Galiè N et al. Eur Respir J. 2019 Jan 24;53(1).
Definite◼ Aminorex◼ Fenfluramine◼ Dexfenfluramine◼ Toxic rapeseed oil◼ Benfluorex◼ Selective serotonin reuptake inhibitorsa
◼ Amphetamine/methamphetamine ◼ Dastinib
Possible◼ Cocaine◼ Phenylpropanolamine◼ St. John’s Wort◼ Interferon 𝛼 and 𝛽◼ Some chemotherapeutic agents such as
alkylating agents (mytomycine C, cyclophosphamide)b
◼ L-tryptophan
a Increased risk of persistent pulmonary hypertension in the newborns of mothers with intake of selective serotonin reuptake inhibitors.bAlkylating agents are possible causes of pulmonary veno-occlusive disease.
Other Risk Factors for PAH
»
»
»
»
»
Sitbon O et al. Am J Respir Crit Care Med, 2008; 177:108-113. Simonneau G et al. J Am Coll Cardiol, 2013; 62 (25 Suppl): D34-D41. Opravil M, Serini D. AIDS, 2008; 22(suppl 3): S35-S40. Lapa M et al. Circulation, 2009; 119: 1518-1523. World Health Organization. Schistosomiasis fact sheet. Available: www.who.int/mediacentre/factsheets/fs115/en/. Accessed: February 23, 2019.
Other Risk Factors for PAH
»
»
»
»
Frost A, et al. Eur Respir J. 2019 Jan 24;53(1). Hadengue A et al. Gastroenterololgy, 1991; 100:520-528. Colle IO et al. Hepatology, 2003; 37:401-409. Budhiraja R, Hassoun PM. Chest, 2003; 23:562-576.
Common Symptoms of PAH
Rich S et al. Ann Intern Med, 1987; 107:216-223. Brown LM et al. Chest, 2011; 140:19-26.
REVEAL = Registry to Evaluate Early And Long-term PAH disease management. US-based observational registry involving 54 academic and community-based treatment centers. 2967 patients enrolled between March 2006 and September 2007; 2525 patients met the hemodynamic Criterial for PAH. 32 of these patients were excluded from this analysis due to a missing date of PAH symptom onset, leaving final study population of this cohort analysis of 2493 patients
98
73
4741
37 36 33
86
2722 22
1713
Diagnose rare causes of PH
Frost A, et al. Eur Respir J. 2019 Jan 24;53(1).
History, symptoms, signs and/or
laboratory tests suggestive of PH
Echocardiographic probability of PH
Low
Consider other causes and/or follow-up
No clinically significant left heart disease or
lung disease
High
PAH: Diagnostic Algorithm
Fast-track referral of selected patient
Consider V/Q scan to screen
for CTEPH
Consider left heart diseases (assess
pre-test probability) and lung disease
Refer to PH expert center
Intermediate
V/Q scan abnormal?
Assess probability of PH
Identify high-risk patients
Diagnose common causes of PH
Yes
No
Frost A, et al. Eur Respir J. 2019 Jan 24;53(1).
Management at PH expert center
Review or perform V/Q scan
Normal perfusion
Multimodality diagnostic assessment
Any mismatched perfusion defect
PAH: Diagnostic Algorithm
CTEPH diagnostic algorithm
Consider other causes
PH not confirmed
RCH for PH diagnosis and hemodynamic characterization
Review by multidisciplinary PH team
PH confirmedPH not confirmed
CTEPH not confirmed
CTEPH confirmed
PH ClassifiedPH Classification
not certain
Appropriate treatment
Consider trial of treatment
Monitor and reassess
Diagnosis of PAH: Signs of PAH on Chest X-ray
Image courtesy of Vallerie McLaughlin, MD.
Echocardiographic Features of PVH vs. PAH
PVH PAH
2-D Echo ◼Dilated LA◼Variable ejection fraction◼ Normal RV size◼LV remains round in short axis
◼Normal LA, LV size ◼Normal-to-high ejection fraction◼RV /RA enlargement◼Septal bowing (systolic>diastole)◼Pericardial effusion
Doppler ◼Variable PASP◼ + MR◼Evidence of LV diastolic
dysfunction
◼Variable PASP◼No MR◼
Forfia PR. Echocardiography in pulmonary vascular disease. In: Yuan JX-J, Garcia JGN, Hales CA, Rish S, Archer SL, West JB, eds. Textbook of Pulmonary Vascular Disease. 1st ed. New York, NY: Springer; 2011:1425-1446.
18
Echocardiographic Characteristics of PAH
Apical 4-chamber view
Importance of Pulmonary Function Testing in PAH
»
»
»
-
»
McGoon M et al. Chest, 2004; 126:14S-34S. The Task Force for the Diagnosis and Treatment of Pulmonary
Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed
by the International Society of heart and Lung Transplantation (ISHLT). Eur heart J, 2009; 30:2493-2537.
Hoeper MM et al. J Am Coll Cardiol, 2013; 62 (25 Suppl):D42-D52.
Blood Tests to Detect Potential Underlying Disease in PAH
Barst RJ et al. J Am Coll Cardiol. 2004; 43(1Suppl):40S-47S. ESC/ERS Task Force. Eur Heart J, 2009; 30:2493-2537.
Blood Test◼Antinuclear antibody (ANA)◼Antiphospholipid antibodies-Lupus anticoagulant, anticardiolipin antibodies
◼HIV serology◼CBC with platelets◼Liver function test◼Thyroid function test◼Hemoglobin electrophoresis, if indicated
V/Q Scan to Exclude Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
»
»
»
Image courtesy of Richard N. Channick, MD.
McGoon M et al. Chest, 2004; 126(1 Suppl): 14S-34S.
Functional Capacity: 6- Minute Walk Test
»
»
»
»
McGoon M et al. Chest, 2004; 126(1 Suppl):14S-34S. ATS Committee on Proficiency on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med, 2002;166:111-117.
Diagnosis of PAH Requires Right Heart Catheterization
McGoon M et al. Chest, 2004; 126:14S-34S. McLaughlin VV et al. J Am Coll Cardiol, 2009; 53:1573-1619.Galiè N et al. Eur Respir J. 2019 Jan 24;53(1).
Right Heart Catheterization◼Required to confirm diagnosis,
calculate resistance, guide therapy
◼Excludes other etiologies of PH- Intracardiac or extracardiac shunts- Left-heart-disease
◼Measures degree of right-heart dysfunction- RAP- CO
Essential Components of Invasive Hemodynamic Assessment◼O2 Saturations (SVC, IVC, RV, PA, SA)◼RAP◼PAP, Systolic, diastolic, mean◼PAWP, or LVEDP◼CO/CI◼PVR
◼Vasodilator challenge should be performed in patients with idiopathic, heritable, and PAH associated with drugs and toxins.
Risk Assessment and Treatment
Martha Kingman, FNP-C, DNP
Family Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, TX
Risk Assessment in PAH
Galiè N, et al. European heart journal. 2016;37(1):67-119.
Determinants of Prognosis(estimated 1-year mortality) Low risk <5% Intermediate risk 5 – 10% High risk >10%
Clinical signs of right heart failure Absent Absent Present
Progression of symptoms No Slow Rapid
Syncope No Occasional syncopeb Repeated syncopec
WHO functional class I, II III IV
6MWD >440 m 165-440 m <165 m
Cardiopulmonary exercise testingPeak VO2 >15 ml/min/kg
(>65% pred.)VE/VCO2 slope <36
Peak VO211-15 ml/min/kg (35 – 65% pred.)
VE/VCO2 slope 36-44.9
Peak VO2 <11 ml/min/kg(<35% pred.)VE/VCO ≥45
NT-proBNP plasma levelsBNP <50 ng/l
NT-proBNP <300 ng/mlBNP 50-300 ng/l
NT-proBNP 300-1400 ng/lBNP >300 ng/l
NT-proBNP >1400 ng/l
Imaging (echocardiography, CMR imaging)RA area <18 cm2
No pericardial effusionRA area 18-26 cm2
No or minimal, pericardial effusionRA area >26 cm2
Pericardial effusion
HemodynamicsRAP <8 mmHg
CI ≥2.5 l/min/m2
SvO2 >65%
RAP 8-14 mmHgCI 2.0-2.4 l/min/m2
SvO2 6—65%
RAP >14 mmHgCI<2.0 l/min/m2
SvO2 <60%
2015 ERS Risk Assessment
Risk Assessment in PAH : REVEAL Calculator
METRIC SCORE
WHO Group I Subgroup APAH-CDT +1 APAH-PoPH +2 APAH-PoPH +2
Demographics & Comorbidities Renal Insufficiency +1 Male age > 60 yrs +2
NYHA/WHO Functional Class I -2 III +1 IV +2
Vital Signs SBP <110 mm Hg +1 HR >92 BPM +1
6-minute Walk Test ≥440 m -1 <165 m +1
BNP <50 pg/ml -2 >180 pg/mL +1
Echocardiogram Pericardial effusion +1
Pulmonary Function Test % prod. Dlco >80 -1 % prod. Dlco <32 +1
Right-heart Catheterization mRAP >20 mm Hg within 1 yr +1 PVR >32 Wood units +2
SUM OF ABOVE:
(STARTING SCORE) +6
= RISK SCORE
Risk scores range from 0 (lowest risk) to 22 (highest risk) LOW AVERAGE MODERATE HIGH VERY HIGH
RISK SCORE 1-7 8 9 10-11 ≥12
PREDICTED 1-YEAR SURVIVAL 95%-100% 90%-<95% 85%-<90% 70%-<85% <70%
APAH=associated PAH; BNP=brain natriuretic peptide; BPM=beats per minute; CTD=connective tissue disease; DLco=carbon monoxide diffusing capacity; FPAH=familial PAH; HR=heart rate; mRAP=mean right atrial pressure; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; PoPH=portopulmonary hypertension; PVR=pulmonary vascular resistance; SBP=systolic blood pressure; WHO=World Health Organization
PAH – General Care
»Patients should be referred to expert PAH centers, ideally prior to starting any PH medications.
»Oxygen- Hypoxia is a potent vasoconstrictor and can elevate PA pressure.
» Fluid/ Volume control – Diuretics, fluid restriction, low salt diet.
» Anticoagulation - Anticoagulation is not recommended in associated forms of PH while in idiopathic and heritable the dates is conflicting and thus decision is on a case by case basis.
» LOW RISK STATUS is GOAL for all patients: Therapy escalation is recommended in the event that low risk status has not been obtained at follow up.
» Pulmonary rehabilitation should be considered in the treatment plan to improve exercise capacity and quality of life.
Klinger R, et al. Chest. January 2019 ( In Press) Available: https://journal.chestnet.org/article/S0012-3692(19)30002-9/fulltext.
Simonneau G, et al. Eur Respir J. 2019;53(1):1801913.
Galiè N et al. Eur Respir J. 2019 Jan 24;53(1).
PAH Treatment Goals
»
»
»
»
»
»
Barst RJ et al. J Am Cll Cardiol, 2009; 54(1 Suppl):S78-S84. McLaughlin VV et al. J Am Coll Cardiol, 2013; 62 (25 Suppl); D73-D91.
Variables That Influence Clinical Management Decisions for PAH
PAH: pulmonary arterial hypertension.
McLaughlin VV et al. J Am Coll Cardiol. 2009;53:1573-1619.
PAH
Disease severity
Comorbidillness
Treatmentgoals
Sideeffects
Route of administration
Clinicianpreference
Galiè N et al. Eur Respir J. 2019 Jan 24;53(1).
Treatment-naïve patient
PAH confirmed by expert center
Acute vasoreactivity test (IPAH/HPAH/DPAH only)
Treatment Algorithm 2018 Nice
General measuresSupportive therapy
Triple sequential combination
High risk
Vasoreactivity
CCB therapy
Non-vasoreactivity
Low or intermediate risk
Residual role for initial
monotherapy
Initial oral combination
Initial Combination
including i.v. PCA
After 3-6 months of treatment
Intermediate or high risk
Low risk
Structured follow-up
After 3-6 months of treatment
Intermediate or high risk
Maximal medical therapy and listing for lung transplantation
Consider referral for lung transplantation
cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate; GTP: guanosine triphosphate; ERA: endothelin receptor antagonist; NO: nitric oxide; PDE-5i: phosphodiesterase-5 inhibitor; PGI2: prostacyclin; sGC: soluble guanylate cyclase
PAH-specific therapies target the three signalling pathways involved in PAH
Adapted from Humbert M, et al. Circulation 2014; 130:2189-2208.
Pro-endothelin-1
ET-1(Vasoconstriction & proliferation)
L-arginine
(Vasodilation & anti-proliferation)
cAMP
PGI2NO
Endothelin
pathway
Prostacyclin
pathway
Nitric oxide
pathway
Arachidonic acid
IP receptor
(Vasodilation & anti-proliferation)
ETAETB
Dual ERASingle ERAcGMPGTP GMP
PDE5sGC
PDE-5 inhibitors
Exogenous NO
sGCstimulator
- +
+
---
Non-prostanoidIP receptor
agonist
PGI2
analogues
+ +
Pathogenesis of PAH: Vasoconstriction
McLaughlin VV, McGoon MD. Circulation. 2006; 114:1417-1431.
VASODILATIONNitric oxideProstacyclin
VASOCONSTRICTIONEndothelinSerotonin
Thromboxane
PAH
Galiè N, et al. European heart journal. 2016;37(1):67-119.
Endothelin Receptor Antagonists (ERAs)
Mechanism of Action »
»
WARNINGS»
»
PROLIFERATION
HYPERTROPHY
FIBROSIS
VASOCONSTRICTION
INFLAMMATION
ET
Endothelin Receptor Antagonists (ERAs)
Drug Route of administration Comment
Bosentan Oral, BID Monitor LFTs before and monthly during therapy, monthly pregnancy testing for all females of child bearing status; REMS; needs specialty pharmacy
Macitentan Oral, QD Monitor before and monthly pregnancy testing for all females of child bearing status; REMS; needsspecialty pharmacy
Ambrisentan Oral, QD Monthly pregnancy testing for all females of child bearing status as clinically indicated; REMS; needs specialty pharmacy
PAH Is Associated With Alterations in Nitric Oxide (NO) Production*
Mason NA et al. J Pathol, 1998; 185:313-318. Giaid A, Saleh D. N Engl J Med .1995 Jul 27;333(4):214-21. McLaughlin VV et al. J Am Coll Cardiol, 2009; 53:1573-1619.Farber HW, Loscalzo J. N Engl J Med, 2004;351:1655-1665.
* These observations are based on reports from in vitro, animal, and human trials. The clinical significance is unknown.
Levels of eNOS in vascular tissues
NOVasoconstriction
Phosphodiesterase-5 (PDE-5) Inhibitors and Guanylate Cyclase Stimulators (sGC)
»
Barst RJ. Vasc Health Risk Manag. 2007;3:11-22.
SP = Requires specialty pharmacy (SP) where medication is delivered to home monthly
DrugRoute of administration Comment
Sildenafil Oral, TID Not be used with nitrates or guanylate cyclase stimulator
Tadalafil Oral, QD Not be used with nitrates or guanylate cyclase stimulator
Riociguat Oral, TID Not be used with nitrates and/or Phosphodiesterase 5 inhibitors (PDE-5Is); REMS; SP
Soluble Guanylate Cyclase (sGC) Stimulator
Mechanism of Action
»
WARNINGS:
»
»
»
FDA approved sGc stimulator:
»
Riociguat package insert
Risk Evaluation and Mitigation Strategy Program (REMS)
»
»
»
»
»
Humbert M, N Engl J Med 2004;351:1425-36.
Prostacyclins
Mechanism of Action (a prostaglandin lipid molecule)»
»»
WARNINGS: »»»
CELL PROLIFERATION
THROMBOSIS
VASOCONSTRICTION
INFLAMMATION
PGI2
Prostacyclin Pathway Meds
NS, normal saline (0.9%); SWFI, sterile water for injection.
NOTE: All IV Prostanoids require a dedicated line; no blood draws; no flushing
Drug Route of administration
Epoprostenol Continuous IV infusion
Continuous IV infusion
Treprostinil Continuous IV infusion
Continuous SC infusion
Inhalation
Oral, BID
Iloprost Inhalation
IP receptor Agonist Oral, BID
Oral Treprostinil (Orenitram)
»
»
Orenitram prescribing information. Available: https://www.orenitram.com/pdf/Orenitram_Full_Prescribing_Information.pdf. Accessed: February 23, 2019.
Selexipag (Uptravi)
»
»
»
Flolan prescribing information. GlaxoSmithKline.
Epoprostenol (Flolan® or Veletri ®)
»
»
»
»
»
»
»
Pain
Erythema
Induration
Treprostinil (Remodulin®) SQ
Infusion Site Pain & Site Reaction
»
-
-
»
»
»
-
Subcutaneous Intravenous
CADD-MS 3
CADD-MS 3
CADD-Legacy
CADD-MS is a trademark and CADD-Legacy is a registered trademark of Smiths Medical System. Cane Crono Five is manufactured by Canè Medical Technology.
Treprostinil (Remodulin®) Pump Options: Relative Size
Implantable Pump for Remodulin
• Newly approved 2018 , currently only available at select PH centers
• Eliminates the risk for central line sepsis
• Allows patients to swim /bathe
• Requires pump refills
https://www.remodulin.com/delivery-options/implantable-pump?gclid=CjwKCAiA8OjjBRB4EiwAMZe6yyewK6NoG8m5DnDpJohe2tb6ScEILQQ5OgdXma5qO02Tmo2WXRSU2hoCcckQAvD_BwE
Possible Dose Adjustments Over Time
Goal of Continuous Infusion Dosing
»
»
»
»
»
Balloon pulmonary angioplasty (BPA)
»
»
»
»
»
Ogawa A, et al. Front Cardiovasc Med. 2015;2:4.
Evolving Paradigm
PAH: Evolving Treatment Paradigm
Sequential Combination
Drug 1
Drugs1 + 2
Drugs1 + 2 + 3
+
+
Upfront Combination
2 or 3 Drugs(especially in patients who
present with high risk features)
Humbert M, Lau EMT, Montani D, et al. Circulation. 2014;130:2189-2208.
The Past Current
Lung Transplantation for PAH
»
»
»
» Patients should be referred for transplant evaluation when they remain intermediate or high risk.
Klinger R, et al. Chest. January 2019 ( In Press) Available: https://journal.chestnet.org/article/S0012-3692(19)30002-9/fulltext.Frost A, et al. Eur Respir J. 2019 Jan 24;53(1).
Long-term Survival of PAH Patients: REVEAL Registry
Farber H, et al. Chest. 2015;148:1043-54.
0
20
40
60
80
100
I II II IV
5-Year Survival by Functional Class I-IV
Previously Diagnosed Newly Diagnosed
Su
rviv
al (
%)
88%
0
20
40
60
80
100
Year 1 Year 5
1- and 5-Year Survival: REVEAL
Previously Diagnosed Newly Diagnosed
90% 86%
65%61%
Su
rviv
al (
%) 72%
76%72%
60%57%
27%
44%
Managing PH Medication SideEffects and Optimizing Therapy
Endothelin Receptor Antagonists: Side Effects
»
»
-
»
-
-
»
-
»
-
*PHA Scientific Leadership Council recommends LFT testing at onset of all treatments for PAH and periodically thereafter, at prescriber’s discretion.
PDE-5: Side Effects
»
»
»
»
»
»
Most side effects can be managed with acetaminophen and anti-diarrhea meds
Contraindicated with use of nitrate
sGC Stimulator: Side Effects
»
»
»
»
»
»
»
»
»
»
Contraindicated in pregnancy and with of nitrates in any form, or with use of PDE inhibitors
Prostacyclins: Adverse Events & Side Effects
Side Effects:
»
»
»
»
»
»
»
Complications of the Delivery System:
»
»Varies according to drug and
route of delivery
Nursing Implications for IV Prostacyclins
»
-
»
»
»
»
Compliance Challenges
»
»
»
»
»
»
Stewart S. Pulmonary Hypertension Association. Available at: http://www.phaonlineuniv.org/Journal/Article.cfm?ItemNumber=786. Accessed: February 23, 2019.
Improving Compliance in PAH
» Assessment of medication adherence with every clinic visit.
» Asking patients to bring pill bottles to reconcile meds initiated or discontinued between visits.
» Utilization of pillboxes, timers, cell phone alarms, or notes for reminders
» Discussion of cultural concepts and social support.
» Get the family involved: review perceived burden on family dynamics.
» Consult with social services to address social or financial factors.
Stewart S. Pulmonary Hypertension Association. Available at: http://www.phaonlineuniv.org/Journal/Article.cfm?ItemNumber=786. Accessed: February 23, 2019.
Conclusions
»
»
»
»
»
McLaughlin VV et al. Circulation, 2009;119:2250-2294. Badesh DB et al. Chest, 2010;137:376-387. Hoeper MM et al. J Am Coll Cardiol, 2013;62 (25 Suppl): D42-D50. Galiè N et al. J Am Coll Cardiol, 2013; 62 (25 Suppl):D60-D72.Simonneau G, et al. Eur Respir J. 2019;53(1):1801913.Frost A, et al. Eur Respir J. 2019 Jan 24;53(1).
Thank You! Questions/Answers